BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Minnema LA, Giezen TJ, Gardarsdottir H, Egberts TCG, Leufkens HGM, Mantel-Teeuwisse AK. Post-marketing dosing changes in the label of biologicals. Br J Clin Pharmacol 2019;85:715-21. [PMID: 30593087 DOI: 10.1111/bcp.13843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Bloem LT, Karomi M, Hoekman J, van der Elst ME, Leufkens HGM, Klungel OH, Mantel-Teeuwisse AK. Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risks. Expert Opin Drug Saf 2021;:1-10. [PMID: 34263667 DOI: 10.1080/14740338.2021.1952981] [Reference Citation Analysis]
2 Minnema LA, Giezen TJ, Gardarsdottir H, Egberts TCG, Leufkens HGM, Mantel-Teeuwisse AK. Post-marketing dosing changes in the label of biologicals. Br J Clin Pharmacol 2019;85:715-21. [PMID: 30593087 DOI: 10.1111/bcp.13843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Contin-Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P. Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. Br J Clin Pharmacol 2021;87:2236-46. [PMID: 33118186 DOI: 10.1111/bcp.14627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]